Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Feb;52(2):e70-e142.
doi: 10.1111/1346-8138.17544. Epub 2024 Dec 20.

English version of clinical practice guidelines for the management of atopic dermatitis 2024

Hidehisa Saeki  1 , Yukihiro Ohya  2 , Hirokazu Arakawa  3 , Susumu Ichiyama  1 , Toshio Katsunuma  4 , Norito Katoh  5 , Akio Tanaka  6 , Hideaki Tanizaki  7 , Yuichiro Tsunemi  8 , Takeshi Nakahara  9 , Mizuho Nagao  10 , Masami Narita  11 , Michihiro Hide  6   12 , Takao Fujisawa  10 , Masaki Futamura  13 , Koji Masuda  14 , Tomoyo Matsubara  15 , Hiroyuki Murota  16 , Kiwako Yamamoto-Hanada  17 , Junichi Furuta  18
Affiliations
Practice Guideline

English version of clinical practice guidelines for the management of atopic dermatitis 2024

Hidehisa Saeki et al. J Dermatol. 2025 Feb.

Abstract

This is the English version of the 2024 clinical practice guidelines for the management of atopic dermatitis (AD). AD is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus. To achieve this, topical anti-inflammatory drugs, such as topical corticosteroids, tacrolimus ointment, delgocitinib ointment, and difamilast ointment, have been used. However, the following treatments should be considered in addition to topical therapy for patients with refractory moderate-to-severe AD: oral cyclosporine, subcutaneous injections of biologics (dupilumab, nemolizumab, tralokinumab), oral Janus kinase inhibitors (baricitinib, upadacitinib, abrocitinib), and phototherapy. In these revised guidelines, descriptions of five new drugs, namely, difamilast, nemolizumab, tralokinumab, upadacitinib, and abrocitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

Keywords: atopic dermatitis; clinical practice guidelines; decision‐making; evidence‐based medicine; treatment.

PubMed Disclaimer

References

REFERENCES

    1. Kawashima M, Takigawa M, Nakagawa H, Furue M, Iijima M, Iizuka H, et al. Guidelines for management of atopic dermatitis. Jpn J Dermatol. 2000;110:1099–1104.
    1. Furue M, Furukawa F, Hide M, Takehara K, Japanese Dermatological Association. Guidelines for therapy for atopic dermatitis 2003. Jpn J Dermatol. 2003;113:451–457.
    1. Furue M, Furukawa F, Hide M, Takehara K. Japanese dermatological association guidelines for therapy of atopic dermatitis 2004. Jpn J Dermatol. 2004;114:135–142.
    1. Furue M, Saeki H, Furukawa F, Hide M, Ohtsuki M, Nakamura T, et al. Guidelines for therapy of atopic dermatitis. Jpn J Dermatol. 2008;118:325–342.
    1. Furue M, Saeki H, Furukawa F, Ohtsuki M, Katayama I, Sasaki R, et al. Guidelines for therapy of atopic dermatitis. Jpn J Dermatol. 2009;119:1515–1534.

Publication types

MeSH terms

LinkOut - more resources